drugset / Trial / NCT06756451
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NaSingle-groupOpen-labelTreatment
Summary
This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies
Timeline
- Start
- 2025-03-25
- Primary completion
- 2028-04-08
- Completion
- 2028-07-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RJK-RT2831 | Unknown | 1 mg | Intravenous |
| Subject | RJK-RT2831 | Unknown | 160 mg | Intravenous |